Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- 1 March 2014
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 233 (1) , 123-129
Abstract
No abstract availableKeywords
Funding Information
- Heart and Stroke Foundation of Canada
This publication has 34 references indexed in Scilit:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)Hepatology, 2008
- Plasma PCSK9 levels correlate with cholesterol in men but not in womenBiochemical and Biophysical Research Communications, 2007
- Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases DegradationJournal of Biological Chemistry, 2007
- Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequencesAmerican Journal of Physiology-Renal Physiology, 2006
- Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartmentProceedings of the National Academy of Sciences, 2005
- Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse LiverJournal of Biological Chemistry, 2004
- Association Between Cholesterol Level and Mortality in Dialysis PatientsJAMA, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003
- Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General PopulationJournal of the American Society of Nephrology, 2002